SEC Form 25-NSE filed by NKGen Biotech Inc.

7/17/25 1:25:20 PM ET

$NKGN

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $NKGN alert in real time by email

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

UNITED STATES

OMB APPROVAL

OMB Number:		3235-0080
Expires:	March 31, 2018
Estimated average burden
hours per response:		1.7

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number

001-40427

Issuer:	NKGen Biotech, Inc.
Exchange:	Nasdaq Stock Market LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address:	1790 Hughes Landing Blvd., Suite 400
	The Woodlands	TEXAS	77380
Telephone number:				612-388-8669

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

Common Stock, Warrants

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

2025-07-17	By	Aravind Menon		Hearings Advisor
Date		Name		Title

¹	Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Get the next $NKGN alert in real time by email

SEC Form 25-NSE filed by NKGen Biotech Inc.

7/17/25 1:25:20 PM ET

$NKGN

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $NKGN alert in real time by email

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

UNITED STATES

OMB APPROVAL

OMB Number:		3235-0080
Expires:	March 31, 2018
Estimated average burden
hours per response:		1.7

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number

001-40427

Issuer:	NKGen Biotech, Inc.
Exchange:	Nasdaq Stock Market LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address:	1790 Hughes Landing Blvd., Suite 400
	The Woodlands	TEXAS	77380
Telephone number:				612-388-8669

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

Common Stock, Warrants

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

2025-07-17	By	Aravind Menon		Hearings Advisor
Date		Name		Title

¹	Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Get the next $NKGN alert in real time by email

SEC Form 25-NSE filed by NKGen Biotech Inc.

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$NKGN

SEC Form 25-NSE filed by NKGen Biotech Inc.

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$NKGN

$NKGN
Press Releases

NKGen Biotech To Present on Allogeneic Enhanced NK Cells without Lymphodepletion in Solid Tumors at the 13th Annual Immuno-Oncology Summit

NKGen Biotech Presents Troculeucel Mechanism of Action with Corresponding Phase 1 Biomarker Data at the Alzheimer's Association International Conference 2025

NKGen Biotech to Present at the Alzheimer's Association International Conference 2025

$NKGN
Insider Trading

Large owner Cfic-2015 Nv Family Investments, Llc bought $2,500,000 worth of shares (19,669,552 units at $0.13), increasing direct ownership by 944% to 21,752,885 units (SEC Form 4)

Chief Executive Officer Song Paul Y. bought $2,650,000 worth of shares (20,849,725 units at $0.13), increasing direct ownership by 12,184% to 21,020,846 units (SEC Form 4)

Large owner Graf Acquisition Partners Iv Llc disposed of 63,634 shares (SEC Form 4)

$NKGN
SEC Filings

NKGen Biotech Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits